Measuring metabolites in index clinical DDI studies
February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…
CertaraFebruary 7, 2025
Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses
This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…
CertaraJanuary 21, 2025
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
CertaraJanuary 9, 2025
